News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology

Al's Comment:

This shows that the convection enhanced delivery methods have improved to the point where they can get the drug, on average,  to over 75% of the tumor, and it should only get better with more experience.  They compare this to the PRECISE trial where the drug only got to about 20% of the tumor.

Here is a link to the poster.

There is a phase 2 clinical trial going on now for this treatment, MDNA55, in patients with recurrent or progressive GBM.

Disclaimer: Medicenna Therapeutics is a sponsor of the Musella Foundation


Posted on: 11/22/2017

Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites



Musella Foundation For Brain Tumor Research & Information, Inc